Shares of Cesca Therapeutics Inc (NASDAQ:KOOL) have been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Analysts have set a twelve-month consensus target price of $6.50 for the company and are anticipating that the company will post ($0.15) EPS for the current quarter, according to Zacks. Zacks has also assigned Cesca Therapeutics an industry rank of 83 out of 256 based on the ratings given to related companies.
Several equities research analysts have recently issued reports on the stock. ValuEngine raised shares of Cesca Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 2nd. HC Wainwright reissued a “buy” rating and issued a $6.50 price objective (up previously from $1.00) on shares of Cesca Therapeutics in a research report on Wednesday.
Cesca Therapeutics (NASDAQ:KOOL) last released its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.13. Cesca Therapeutics had a negative net margin of 98.84% and a negative return on equity of 77.30%. The company had revenue of $4.31 million during the quarter, compared to analyst estimates of $3.40 million. On average, sell-side analysts anticipate that Cesca Therapeutics will post -2 earnings per share for the current fiscal year.
Cesca Therapeutics Company Profile
Cesca Therapeutics Inc develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products.
Featured Article: How does the Beige Book influence monetary policy?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.